Cargando…

Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake in a selected cohort of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavano, Francesca, Fontana, Andrea, Pellegrini, Fabio, Burbaci, Francesca Paola, Rappa, Francesca, Cappello, Francesco, Copetti, Massimiliano, Maiello, Evaristo, Lombardi, Lucia, Graziano, Paolo, Vinciguerra, Manlio, di Mola, Fabio Francesco, di Sebastiano, Pierluigi, Andriulli, Angelo, Pazienza, Valerio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172900/
https://www.ncbi.nlm.nih.gov/pubmed/25199538
http://dx.doi.org/10.1186/s12967-014-0248-4
_version_ 1782336096412106752
author Tavano, Francesca
Fontana, Andrea
Pellegrini, Fabio
Burbaci, Francesca Paola
Rappa, Francesca
Cappello, Francesco
Copetti, Massimiliano
Maiello, Evaristo
Lombardi, Lucia
Graziano, Paolo
Vinciguerra, Manlio
di Mola, Fabio Francesco
di Sebastiano, Pierluigi
Andriulli, Angelo
Pazienza, Valerio
author_facet Tavano, Francesca
Fontana, Andrea
Pellegrini, Fabio
Burbaci, Francesca Paola
Rappa, Francesca
Cappello, Francesco
Copetti, Massimiliano
Maiello, Evaristo
Lombardi, Lucia
Graziano, Paolo
Vinciguerra, Manlio
di Mola, Fabio Francesco
di Sebastiano, Pierluigi
Andriulli, Angelo
Pazienza, Valerio
author_sort Tavano, Francesca
collection PubMed
description BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake in a selected cohort of patients with PDAC, with well-defined clinical-pathological features. METHODS: mRNA levels of hENT1, CHOP, MRP1 and DCK were evaluated by means of qRT-PCR in matched pairs of tumor and adjacent normal tissue samples collected from PDAC patients treated with gemcitabine after surgical tumor resection. To detect possible interaction between gene expression levels and to identify subgroups of patients at different mortality/progression risk, the RECursive Partitioning and Amalgamation (RECPAM) method was used. RESULTS: RECPAM analysis showed that DCK and CHOP were most relevant variables for the identification of patients with different mortality risk, while hENT1 and CHOP were able to identify subgroups of patients with different disease progression risk. Conclusion: hENT1, CHOP, MRP1 and DCK appear correlated to PDAC, and this interaction might influence disease behavior.
format Online
Article
Text
id pubmed-4172900
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41729002014-09-25 Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients Tavano, Francesca Fontana, Andrea Pellegrini, Fabio Burbaci, Francesca Paola Rappa, Francesca Cappello, Francesco Copetti, Massimiliano Maiello, Evaristo Lombardi, Lucia Graziano, Paolo Vinciguerra, Manlio di Mola, Fabio Francesco di Sebastiano, Pierluigi Andriulli, Angelo Pazienza, Valerio J Transl Med Research BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake in a selected cohort of patients with PDAC, with well-defined clinical-pathological features. METHODS: mRNA levels of hENT1, CHOP, MRP1 and DCK were evaluated by means of qRT-PCR in matched pairs of tumor and adjacent normal tissue samples collected from PDAC patients treated with gemcitabine after surgical tumor resection. To detect possible interaction between gene expression levels and to identify subgroups of patients at different mortality/progression risk, the RECursive Partitioning and Amalgamation (RECPAM) method was used. RESULTS: RECPAM analysis showed that DCK and CHOP were most relevant variables for the identification of patients with different mortality risk, while hENT1 and CHOP were able to identify subgroups of patients with different disease progression risk. Conclusion: hENT1, CHOP, MRP1 and DCK appear correlated to PDAC, and this interaction might influence disease behavior. BioMed Central 2014-09-10 /pmc/articles/PMC4172900/ /pubmed/25199538 http://dx.doi.org/10.1186/s12967-014-0248-4 Text en © Tavano et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Tavano, Francesca
Fontana, Andrea
Pellegrini, Fabio
Burbaci, Francesca Paola
Rappa, Francesca
Cappello, Francesco
Copetti, Massimiliano
Maiello, Evaristo
Lombardi, Lucia
Graziano, Paolo
Vinciguerra, Manlio
di Mola, Fabio Francesco
di Sebastiano, Pierluigi
Andriulli, Angelo
Pazienza, Valerio
Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients
title Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients
title_full Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients
title_fullStr Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients
title_full_unstemmed Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients
title_short Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients
title_sort modeling interactions between human equilibrative nucleoside transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172900/
https://www.ncbi.nlm.nih.gov/pubmed/25199538
http://dx.doi.org/10.1186/s12967-014-0248-4
work_keys_str_mv AT tavanofrancesca modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT fontanaandrea modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT pellegrinifabio modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT burbacifrancescapaola modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT rappafrancesca modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT cappellofrancesco modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT copettimassimiliano modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT maielloevaristo modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT lombardilucia modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT grazianopaolo modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT vinciguerramanlio modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT dimolafabiofrancesco modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT disebastianopierluigi modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT andriulliangelo modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients
AT pazienzavalerio modelinginteractionsbetweenhumanequilibrativenucleosidetransporter1andotherfactorsinvolvedintheresponsetogemcitabinetreatmenttopredictclinicaloutcomesinpancreaticductaladenocarcinomapatients